anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INVENTORS                               HERBERT LAPIDUS                                     AND    ALBERT SHANSKY     FOR:   CATALYZED BIZMUTH DYE SYSTEM               FOR HUMAN HAIR     ABSTRACT    A dyeing  system for human hair is provided comprising a bismuth  salt,  a  sulfur  source,  such  as  elemental  sulfur  or thiosulfate, a complexing agent such as triethanolamine, product enhancers, and a catalyst which has a chemical structure having either an oxygen atom possessing a resonating double bond or an oxygen atom of an ether group attached to a carbon atom,  such catalyst being characterized by a high degree of solubility in water and having a molecular weight of from about 50 to about 170.    The ability of human hair to be effectively colored by a bismuth containing dyeing system involves a complex interaction of a number of components in the dyeing system and requires the presence of an excess of sulfur ions in order to provide the necessary sulfur  for  the  formation  of  bismuth  sulfide  or trisulfide in the hair fibers.  The catalyst component described hereinbefore provides a convenient means  whereby the negative oxygen of the catalyst may attract the positive bismuth ion and the positive carbon of the catalyst may attract  the  negative sulfur ion.  After penetration of the hair fiber and subsequent exsiccation, the attracted ions will unite to form the colored bismuth sulfide or trisulfide component within the hair fiber.    This invention provides for a novel system for dyeing human hair  comprising  a  bismuth  salt  and  a catalyst component  in admixture with a composition comprising triethanolamine, at least one sulfur containing component, Triton X 100* , and water.     * a trade mark
SINGULAIR has been evaluated for safety in 476 pediatric patients 6 to 14 years of age. Cumulatively, 289 pediatric patients were treated with SINGULAIR for at least 6 months, and 241 for one year or longer in clinical trials. The safety profile of SINGULAIR in the 8-week, double-blind, pediatric efficacy trial was generally similar to the adult safety profile. In pediatric patients 6 to 14 years of age receiving SINGULAIR, the following events occurred with a frequency ≥2% and more frequently than in pediatric patients who received placebo, regardless of causality assessment: pharyngitis, influenza, fever, sinusitis, nausea, diarrhea, dyspepsia, otitis, viral infection, and laryngitis. The frequency of less common adverse events was comparable between SINGULAIR and placebo. With prolonged treatment, the adverse experience profile did not significantly change.

In studies evaluating growth rate, the safety profile in these pediatric patients was consistent with the safety profile previously described for SINGULAIR. In a 56-week, double-blind study evaluating growth rate in pediatric patients 6 to 8 years of age receiving SINGULAIR, the following events not previously observed with the use of SINGULAIR in this age group occurred with a frequency ≥2% and more frequently than in pediatric patients who received placebo, regardless of causality assessment: headache, rhinitis (infective), varicella, gastroenteritis, atopic dermatitis, acute bronchitis, tooth infection, skin infection, and myopia.
The present invention relates to medicinal toothpaste for treating oral diseases, wherein each 100 portions comprise 1 to 2 portions of Chinese medicine mint, 1 to 2 portions of bugbane, 1 to 2 portions of indigo, 1 to 2 portions of cyperus tuber, 2 to 4 portions of dry continuous grass, 2 to 4 portions of scurfpea fruit, and a surplus toothpaste substrate. Teeth are massaged by a tooth brushing mode. The medicinal toothpaste for treating oral diseases has a synergistic function for prompting gingivae and tooth roots to absorb medicine, improving the blood circulation of periodontal tissue, and eliminating bacterial spots. The medicinal toothpaste for treating oral diseases resists fungi and suppresses anaerobic bacteria and aerobic bacteria such as golden staphylococci, white staphylococci, etc. The medicinal toothpaste for treating oral diseases stops blood, strengthening the teeth, and quickly restores various cell prototypes. Each structure continuously regenerates for evacuating pus, promoting tissue, enhancing the function of a human body, and enhancing immunity. Consequently, the goals of prevention and treatment are achieved. The medicinal toothpaste for treating oral diseases has 92% of a cure rate and 100% of an effective rate for gingivitis, parodontitis, periodontal abscess, tooth essence hypersensitiveness and oral ulcer by treating various oral diseases. The present invention has good preventing and curative efficacy for periodical periodontitis, pulpitis, halitosis and decayed teeth.
Procedure for preparation of N- (9,10-dihydro-4h-benzo (4,5) ciclohepta (1,2b) thiophen-4-methyl) formamide, of formula (I). A compound of formula (II) is reduced, in which x and y are sulfur or a group of formula (III), in a sodium amalgam and in a solvent solvent means, at temperature of 40-120c. The acid obtained is reacted with a dissolution of sodium azide in water, ethyl chloroformate and triethylamine, in a dissolution of sodium azide in water, ethyl chlorophythmiate and triethylamine, in tetrahidofuran. The pruduct is warmed to ebullición in an inert solution and reduced with sodium borohidride in 1,2-dimetoxyethane as a solvent. It is used as a precursor and intermediary in the elaboration of different pharmaceutical preparations. (Machine-translation by Google Translate, not legally binding)
Thirty young healthy males from the altitude of 3700 meters will be allocated to the High Altitude Sham group. They will undergo a sham RIC procedure during which bilateral arm cuffs are inflated to a pressure of 60 mmHg for five cycles of 5 min, followed by 5 min of relaxation of the cuffs, performed twice a day for a total of 7 days.
PURPOSE:To coat a lesion, to guide a blood capillary, etc., in an early period and to prevent bacterial infection by depositing the material which are extracted from the serum, plasma or platelet and bind to heparin to a base material contg. collagen or the collagen and the heparin. CONSTITUTION:This wound healing material is formed of the base material contg. the fraction eluted by a 0.5MNaCl soln. and/or 1.0MNaCl soln. by bonding the liquid extracted from the serum, plasma or platelet and the collagen and heparin thereto. The wound healing material strongly supports cell proliferation and has high bioaffinity when the wound heeling material is applied in the vital body and, therefore, the material contributes to the formation of the granulation layer and skin formation and accelerates heeling when the material is applied as, for example, the artificial skin. Further, the wound healing material is lined by a backing layer having air permeability, by which the generation of the leakage of the body fluid, bacterial infection, etc., is minimized when the material is applied as the artificial skin.
The invention belongs to the field of pharmacy, and specifically relates to a pectin-adriamycin coniuncate lyophilized preparation, and a preparation method thereof. In order to solve the dissolving difficulty of pectin-adriamycin coniuncate (PAC for short), to improve the biomass utilance, and to produce preparations conveniently, the inventor produces PAC into a nano-sized suspension. However, because the long-term stability of the nano-sized suspension is poor, the nano-sized suspension is then produced into a lyophilized preparation. The preparation method comprises the steps that: PAC which is hard to dissolve is prepared into a suspension or a nano-sized suspension; a lyophilizing proppant is added to the suspension or the nano-sized suspension; lyophilization is carried out upon the suspension, and a lyophilized preparation is obtained. When the nano-sized suspension is prepared into the lyophilized preparation, stability of nano-particle size is improved, and stability of drug loading capacity is improved. The invention assists in providing a novel scheme for the clinic application of PAC.
The invention discloses an orally disintegrating tablet containing Istradefylline and a preparation method thereof. The tablet contains a water-soluble filler, a binder, a disintegrating agent, a lubricant, and an odor mask. A solid dispersion technology is employed to improve the taste. The tablet has the characteristics of good taste, good oral compliance, rapid onset, and is applicable to the treatment of Parkinson's disease. The invention also provides a preparation method. The method has simple process and low cost, and belongs to the medical technical fields of medical science and pharmacy.
Early induction response assessment with day-21 bone marrow (D21-BM) is commonly performed in patients with FLT3-mutated acute myeloid leukaemia (AML), where detection of residual leukaemia (RL; blasts ≥5%) typically results in the administration of a second induction course. However, whether D21-BM results predict for RL at the end of first induction has not been systematically assessed. This study evaluates the predictive role of D21-BM morphology in detecting RL following first induction. Between August 2018 and March 2022, all patients with FLT3-AML receiving 7+3 plus midostaurin, with D21-BM performed, were identified. Correlation between D21-BM morphology vs D21-BM ancillary flow/molecular results, as well as vs D28-BM end of first induction response, were retrospectively reviewed. Subsequently, D21-BMs were subjected to anonymised morphological re-assessments by independent haematopathologists (total in triplicate per patient). Of nine patients included in this study, three (33%) were designated to have RL at D21-BM, all of whom entered complete remission at D28-BM. Furthermore, only low-level measurable residual disease was detected in all three cases by flow or molecular methods at D21-BM, hence none proceeded to a second induction. Independent re-evaluations of these cases failed to correctly reassign D21-BM responses, yielding a final false positive rate of 33%. In summary, based on morphology alone, D21-BM assessment following 7+3 intensive induction plus midostaurin for FLT3-AML incorrectly designates RL in some patients; thus correlating with associated flow and molecular results is essential before concluding RL following first induction. Where remission status is unclear, repeat D28-BMs should be performed.
Ocular and auditory disturbances have been reported when deferoxamine mesylate was administered over prolonged periods of time, at high doses, or in patients with low ferritin levels. The ocular disturbances observed have been blurring of vision; cataracts after prolonged administration in chronic iron overload; decreased visual acuity including visual loss, visual defects, scotoma; impaired peripheral, color, and night vision; optic neuritis, cataracts, corneal opacities, and retinal pigmentary abnormalities. The auditory abnormalities reported have been tinnitus and hearing loss including high frequency sensorineural hearing loss. In most cases, both ocular and auditory disturbances were reversible upon immediate cessation of treatment (see PRECAUTIONS/Information for Patients and ADVERSE REACTIONS/Special Senses).

Visual acuity tests, slit-lamp examinations, funduscopy and audiometry are recommended periodically in patients treated for prolonged periods of time. Toxicity is more likely to be reversed if symptoms or test abnormalities are detected early.

Increases in serum creatinine (possibly dose-related), acute renal failure and renal tubular disorders, associated with the administration of deferoxamine, have been reported in postmarketing experience (see ADVERSE REACTIONS). Monitor patients for changes in renal function.

High doses of deferoxamine mesylate and concomitant low ferritin levels have also been associated with growth retardation. After reduction of deferoxamine mesylate dose, growth velocity may partially resume to pretreatment rates (see PRECAUTIONS/Pediatric Use).

Adult respiratory distress syndrome, also reported in children, has been described following treatment with excessively high intravenous doses of deferoxamine mesylate in patients with acute iron intoxication or thalassemia.
An aronia melanocarpa extract. Study volunteers will receive a daily oral dose of 160 mg AME for 6 weeks.
We have previously shown that the pro-oxidative aldehyde acrolein is a critical factor in MS pathology. In this study, we found that the acrolein scavenger hydralazine (HZ), when applied from the day of induction, can suppress acrolein and alleviate motor and sensory deficits in a mouse experimental autoimmune encephalomyelitis (EAE) model. Furthermore, we also demonstrated that HZ can alleviate motor deficits when applied after the emergence of MS symptoms, making potential anti-acrolein treatment a more clinically relevant strategy. In addition, HZ can reduce both acrolein and MPO, suggesting a connection between acrolein and inflammation. We also found that in addition to HZ, phenelzine (PZ), a structurally distinct acrolein scavenger, can mitigate motor deficits in EAE when applied from the day of induction. This suggests that the likely chief factor of neuroprotection offered by these two structurally distinct acrolein scavengers in EAE is their common feature of acrolein neutralization. Finally, up-and-down regulation of the function of aldehyde dehydrogenase 2 (ALDH2) in EAE mice using either a pharmacological or genetic strategy led to correspondent motor and sensory changes. This data indicates a potential key role of ALDH2 in influencing acrolein levels, oxidative stress, inflammation, and behavior in EAE. These findings further consolidate the critical role of aldehydes in the pathology of EAE and its mechanisms of regulation. This is expected to reinforce and expand the possible therapeutic targets of anti-aldehyde treatment to achieve neuroprotection through both endogenous and exogenous manners.
Effective communication between patients and physicians is critical to successful health outcomes. Limited English proficiency (LEP) is defined by the U.S. Census Bureau as anyone who reported speaking English less than "very well". There are more than 25 million people (approximately 1 in 11 Americans) with LEP in the United States.1 LEP patients are among the most vulnerable populations. The language barrier experienced by LEP patients hinders effective communication, impedes access to care, and impacts health care delivery.6 Research has shown that LEP patients are likely to consume more health care services7; however, they receive lower quality of care and have poorer outcomes compared to English-proficient patients on various measures: understanding of treatment plans and diseases processes, satisfaction, and incidence of medical errors.3,5, This language-based inequity in LEP patients also hampers shared decision-making, a process in which physicians and patients make decisions together, balancing the risks and benefits with patient preferences and values.6-7 Shared decision-making is encouraged by the Institute of Medicine and US Preventative Services to foster patient autonomy and engagement.6 Similarly, the American College of Obstetricians and Gynecologists emphasizes the importance of creating a partnership with patients.7 Research indicates that patients want to be more involved in the decision-making process but might feel that they do not have the capability to do so.8 Furthermore, the ability of patients to engage in the shared decision-making process also depends on their health literacy. It is estimated that one-third to one-half of the U.S. adult population has low health literacy or a limited capacity to obtain, process, and understand the basic health information and services needed to make informed health decisions.8 While low health literacy affects individuals across the spectrum of socio-demographics, it disproportionately affects those with LEP.9 A knowledge gap exists in our understanding of LEP patients' roles in decision-making since most research on decision-making itself often excludes non-English speakers from study participation. The few published reports in the oncology literature have suggested that Latinas experience barriers to informed treatment decision-making related to literacy, language, and acculturation.2,8 Hawley ST et al. (2008), in a survey of 2030 women with breast cancer, found that Spanish-preferred Latinas were more likely to report too little involvement, higher dissatisfaction, and more regrets compared to English-preferred Latinas, African Americans, and Caucasians.9 Research has shown that patients who take a more active role in their care are often more satisfied, have a better understanding of treatment plans, and experience greater improvement in health and patient-centered outcomes than do passive patients.10 Therefore, understanding these preferences, particularly in an LEP population, is necessary to meet patients' decision-making expectations, navigate discussions about treatment options, and increase patient satisfaction with the decision-making process.
All parents will be scheduled for 12 individual Community Reinforcement and Family Training for parents (CRAFT-P) training sessions within 120 days and allowed to use up to 6 additional emergency sessions at any time up to the 12-mo follow-up. The first session will last 90 min; the remaining sessions will be 50 - 60 min in duration. Emergency sessions typically last 30 - 60 min and are used to assist the parent with crisis situations during the treatment period (e.g., adolescent violence, arrest) or for booster sessions after.
Anesthesia will be induced with bolus infusion using propofol, sufentanil and cis-atracurium intravenously. The patients will be intubated subsequently. TOF (T4/T1) will be calculated continuously using muscle relaxation monitoring. Anesthesia are maintained with a combination of sevoflurane, propofol, sufentanil and cis-atracurium. Anti-emetic and opioids will be routinely administrated prior to abdominal closure. Neostigmine will be administrated for reversing the residual neuromuscular blockade after the patient get his breath. Tracheal extubating is indicated by a TOF value above 70% in addition to other physical signs.
The safety and effectiveness of cefepime in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, pneumonia, and as empiric therapy for febrile neutropenic patients have been established in the age groups 2 months up to 16 years. Use of Cefepime Injection in these age groups is supported by evidence from adequate and well-controlled studies of cefepime in adults with additional pharmacokinetic and safety data from pediatric trials [see Clinical Pharmacology (12)].

Safety and effectiveness in pediatric patients below the age of 2 months have not been established. There are insufficient clinical data to support the use of Cefepime Injection in pediatric patients under 2 months of age or for the treatment of serious infections in the pediatric population where the suspected or proven pathogen is Haemophilus influenzae type b. In those patients in whom meningeal seeding from a distant infection site or in whom meningitis is suspected or documented, an alternate agent with demonstrated clinical efficacy in this setting should be used.

Cefepime Injection in Galaxy Container should be used only in pediatric patients who require the entire 1 or 2 g dose and not any fraction thereof.
INTRODUCTION: Frontotemporal lobar degeneration (FTLD) encompasses behavioral variant frontotemporal dementia (bvFTD), progressive supranuclear palsy, corticobasal syndrome/degeneration, and primary progressive aphasias (PPAs). We cross-validated fluid biomarkers and neuroimaging.
METHODS: Seven fluid biomarkers from cerebrospinal fluid and serum were related to atrophy in 428 participants including these FTLD subtypes, logopenic variant PPA (lvPPA), Alzheimer's disease (AD), and healthy subjects. Atrophy was assessed by structural magnetic resonance imaging and atlas-based volumetry.
RESULTS: FTLD subtypes, lvPPA, and AD showed specific profiles for neurofilament light chain, phosphorylated heavy chain, tau, phospho-tau, amyloid beta1-42 from serum/cerebrospinal fluid, and brain atrophy. Neurofilaments related to regional atrophy in bvFTD, whereas progranulin was associated with atrophy in semantic variant PPA. Ubiquitin showed no effects.
DISCUSSION: Results specify biomarker and atrophy patterns in FTLD and AD supporting differential diagnosis. They identify neurofilaments and progranulin in interaction with structural imaging as promising candidates for monitoring disease progression and therapy.
HIGHLIGHTS: Study cross-validated neuroimaging and fluid biomarkers in dementia. Five kinds of frontotemporal lobar degeneration and two variants of Alzheimer's disease. Study identifies disease-specific fluid biomarker and atrophy profiles. Fluid biomarkers and atrophy interact in a disease-specific way. Neurofilaments and progranulin are proposed as biomarkers for diagnosis and therapy.
The invention discloses a bovine brucellosis outer membrane protein Omp22 gene, and a preparation method and application of the gene, relates to a gene and in particular relates to an outer membrane protein Omp22 gene expressed on the outer membrane of bovine brucellosis and a preparation method and a use of the gene. The invention provides a bovine brucellosis outer membrane protein Omp22 and a coding gene thereof. The coding gene has the nucleotide sequence used for coding the amino acid sequence of the outer membrane protein Omp22. The invention also provides a method for preparing the Omp22 gene by use of the recombinant technology. The method comprises the steps of operably connecting the purified nucleotide sequence for coding the active peptide with the Omp22 to an expression regulation sequence to form an expression vector of the Omp22, transferring the expression vector in a host cell to form a recombinant cell of the outer membrane protein Omp22, and culturing the recombinant cell. The invention further provides application of the bovine brucellosis outer membrane protein Omp22 and the coding sequence of the Omp22.
PATENT                         ABSTRACT      A method of identifying epitopes to gene products, specifically the human retinoblastoma (Rb) gene and the corresponding antigenic polypeptides.  The amino acid sequence has a combination of low solubility and high hydrophilicity.  Highly specific high-affinity anti-Rb-IgGs have been purified using the techniques of this invention.  The anti-Rb-IgGs have been used to immuno-precipitate and produce Western Blot patterns associated with normal and abnormal Rb proteins.  The method and products of this invention can be used in various diagnostic procedures.     APPLN3/BAYA,008
Gallium Citrate Ga 67, with no carrier added, has been found to concentrate in certain viable primary and metastatic tumors as well as focal sites of infection. The mechanism of concentration is unknown, but investigational studies have shown that gallium Ga-67 accumulates in lysosomes and is bound to a soluble intracellular protein.

It has been reported in the scientific literature that following intravenous injection, the highest tissue concentration of gallium Ga-67 - other than tumors and sites of infection - is the renal cortex. After the first day, the maximum concentration shifts to bone and lymph nodes and after the first week, to liver and spleen. Gallium Ga-67 is excreted relatively slowly from the body. The average whole body retention is 65 percent after seven days, with 26 percent having been excreted in the urine and 9 percent in the stools.